Clinical trials: High-risk Medications
Alcohol Dependence
CRF1 Antagonist GSK561679 in Alcoholism
Objective: To evaluate GSK561679, an orally available, brain penetrant selective CRH1 antagonist for its ability to reduce alcohol craving in recently detoxified alcohol dependent women in response to stress or alcohol-associated…
- Trial name
- NCT01187511
- Testing
- GSK561679
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Heart Failure, Atrial Fibrillation
Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Atrial fibrillation and heart failure are two common heart conditions that are associated with an increase in death and suffering. When both of these two conditions occur in a patient the patient's prognosis is poor.
- Trial name
- RAFT-AF (NCT01420393)
- Testing
- Rhythm control, Rate Control
- Where
- 21 sites in Brazil, Canada and 2 more
- Volunteers
- 411 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Infusion Safety, Medication Safety
Air-in-Line Alarms During Antineoplastic Drug Infusion
The goal of this observational study is to evaluate infusion alarms, particularly air-in-line alarms, during antineoplastic drug infusion in oncology care settings.
- Conditions
- Infusion Safety, Medication Safety, Antineoplastic Drug Administration, Air-in-Line Alarm
- Trial name
- AIR-ONC (NCT07718711)
- Testing
- Routine Infusion Technologies
- Where
- 5 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Associazione Italiana Infermieri di Area Oncologica
Breast Cancer
Exercise, Cancer and Cognition: The ECCO-Study
The "ECCO"-study evaluates the efficacy of simultaneous controlled exercise during neo/-adjuvant chemotherapy in breast cancer patients and its effects on neurocognition.
- Trial name
- ECCO (NCT04789187)
- Testing
- High-Intensity-Interval-Training, General Physical Activity Recommendations
- Where
- Austria
- Volunteers
- 126 people
- Sponsor
- Johannes Kepler University of Linz
ACS - Acute Coronary Syndrome, Ticagrelor
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to…
- Conditions
- ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota, Platelet Aggregation
- Trial name
- FLORA-ACS (NCT07203846)
- Testing
- Rifaximin
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Diabetic Nephropathy
Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes
OBJECTIVES: I. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community. II.
- Trial name
- NCT00004266
- Testing
- Lisinopril, Nifedipine, Simvastatin
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Depression, Obesity
Research Aimed at Improving Both Mood and Weight
The RAINBOW study is an NIH R01-funded randomized controlled trial to evaluate the clinical and cost effectiveness and implementation potential of a primary care integrated multicondition intervention program to help improve mood…
- Trial name
- RAINBOW-ENGAGE (NCT02246413)
- Testing
- RAINBOW Intervention Program
- Where
- 2 sites in United States
- Volunteers
- 409 people
- Sponsor
- Palo Alto Medical Foundation
Multimorbidity, Mental Health Issue
Impact of Multi-component Interventions on Populations With Mental Health Symptoms and High-risk COPD
Study Participants: High-risk COPD population with mental health symptoms, defined as individuals whose score of COPD-SQ ≥ 16, whose age is 35 and above, and whose Warwick-Edinburgh Mental Well-being Scale <45 .
- Conditions
- Multimorbidity, Mental Health Issue, Multi-component Interventions
- Trial name
- POPMIX-MH (NCT06458218)
- Testing
- Multi-component Interventions
- Where
- China
- Volunteers
- 3,571 people
- Sponsor
- Peking Union Medical College
Nausea, Vomiting
Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting
Title of the study Aprepitant for prevention of acute and delayed nausea and vomiting: a phase III, double-blind, randomized, placebo-controlled trial in patients receiving a high-emetogenic dose of cyclophosphamide for…
- Trial name
- PG-APRE1 (NCT01088022)
- Testing
- Aprepitant, Palonosetron, Dexamethasone
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Azienda Ospedaliera di Perugia
High-risk Surgery
Association of Intraoperative Hemodynamic Characteristics to Postoperative Complications and Mortality
Worldwide, about 400 million major surgeries are performed annually. The scarce data available in the literature still suggest high postoperative morbidity and mortality, even in Europe.
- Trial name
- HeCoMo (NCT06355362)
- Volunteers
- 1,000 people
- Sponsor
- Kliniken Essen-Mitte
Pancreatic Neoplasms, Pancreatic Cancer
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
This is a phase II study. It is designed to provide information about if high-dose ascorbate (vitamin C) increases survival for pancreatic cancer patients.
- Trial name
- PACMAN-II (NCT01515046)
- Testing
- Gemcitabine with escalating ascorbic acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Joseph J. Cullen
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
This is a multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus rosuvastatin in participants with high cholesterol.
- Trial name
- NCT00479713
- Testing
- ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium
- Volunteers
- 618 people
- Sponsor
- Organon and Co
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Directly Observed Therapy, HIV Infections
Directly Observed Therapy in High Risk Populations in Newark, NJ
30 patients with poor antiretroviral therapy compliance will be identified from our pool of patients at Saint Michael's Medical Center and be given Directly observed therapy.
- Trial name
- NCT00285883
- Testing
- Invirase, Norvir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Saint Michael's Medical Center
Healhty
Effectiveness of Artificial Intelligence Integrated Mixed Reality-based High-Alert Medications Management Simulation Program
The goal of this clinical trial is to learn if a Artificial Intelligence integrated Mixed Reality-based High-Alert Medications Management Simulation Program (AIMR-HAM) helps hospital nurses manage high-alert medicines (HAMs) more…
- Trial name
- AIMR-HAM (NCT07390461)
- Testing
- Artificial Intelligence integrated Mixed Reality-based Simulation Program, Standard medication-management education
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chonnam National University Hospital
Stigma, Social, Drug Abuse Illicit
Lower Intersecting HIV-related Stigmas to Facilitate Treatment as Prevention (LIFT)
The purpose of this study is to reduce HIV transmission risk among people who inject drugs (PWID) through a multilevel intervention known as LIFT.
- Conditions
- Stigma, Social, Drug Abuse Illicit, HIV (Human Immunodeficiency Virus)
- Trial name
- LIFT (NCT07541131)
- Testing
- LIFT for People Who Use Drugs, LIFT for MMT Providers
- Where
- Kyrgyzstan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Hepatitis B Vaccination
Immunogenicity of Hepatitis B Vaccination Among Drug Users
Uptake, adherence, and completion of vaccination among drug users were low, and their immune function and immune response to hepatitis B vaccination were also suboptimal, indicating that the current practice of hepatitis B…
- Trial name
- NCT02959775
- Testing
- 60 µg dose hepatitis B vaccine, 20 µg dose hepatitis B vaccine
- Volunteers
- 480 people
- Sponsor
- Shanxi Medical University
Hyperlipidemia
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density…
- Trial name
- MENDEL-2 (NCT01763827)
- Testing
- Evolocumab, Ezetimibe
- Where
- 83 sites in United States, Australia and 8 more
- Volunteers
- 615 people
- Sponsor
- Amgen
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04037254
- Testing
- Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib
- Where
- 95 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- NRG Oncology
Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus
Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy
Background: The human immunodeficiency virus (HIV) causes acquired immune deficiency syndrome (AIDS). Combination antiretroviral therapy (ART) drugs treat HIV infection.
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus
- Trial name
- NCT01976715
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)